BABS engagement with industry and government facilitates BABS faculty and students to develop the skills and networks to translate and commercialise biotechnology and life science research.
BABS Advisory Committee
Through consultation with our industry advisory committee, BABS research and education strategies are aligned with the needs of the industry.
BABS Faculty and alumni are involved in commercial ventures in a number of start-ups and established companies, including:
- Bondi Bio https://www.bondi.bio/ is a solar bioengineering company focused on producing traditionally plant-derived Natural Products from light, water and carbon dioxide.
- Continuum Biosciences https://continuumbio.com/team is focussed on developing innovative drugs to improve mitochondrial health by targeting metabolic disease and disorders.
- Continual-G https://au.continualg.com/ manufactures a proprietary form of Gamma – Glutamylcysteine (GCG) which is required to produce the powerful antioxidant Glutathione, a critical molecule required to maintain health.
- Denova Sciences https://denovasciences.com/ offers skin testing services using a proprietary in vitro human skin technology. Read about this start-up success here.
Partnerships with Industry
BABS has many partnerships with industry, a number of which have been awarded Australian Research Council (ARC) Linkage Projects Grants, supporting partnerships with Microbiogen Pty Ltd, Royal Botanic Gardens and Domain Trust and Nutromics Pty ltd. Our Recombinant Products Facility (RPF) provides protein production and purification services for academic and industry researchers. Other partnerships include;
Bondi Bio https://www.bondi.bio/
Drop Bio https://www.dropbio.com/ An Australian digital health and biotechnology company focused on measuring and tracking chronic inflammation, has taken up residency at BABS to enable companies to access and utilise university facilities and forge deeper relationships between the University and industry partners.
AusBiotech https://www.ausbiotech.org/ is the leading Australian industry body representing and advocating for organisations in the global biotechnology and life sciences industry; BABS Faculty are represented on the NSW AusBiotech Committee.
AusBiotech website offer key industry facts and membership as an Academic or Student https://www.ausbiotech.org/member-services/become-a-member offers free access to State-based networking events, student volunteering opportunities, industry news, investments and the BiotechTalksLibrary covering up-to-date information on the industry.
The Bridge Program
BABS at UNSW is one of 13 national partners of The Bridge Program https://research.qut.edu.au/bridge/
The Bridge Program delivers education programs that equips early- and mid-career researchers, academics and entrepreneurs with the necessary knowledge, skills and to enable successful commercialisation of Australian pharmaceutical and biotechnology research.
The Bridge Program is supported by the government body MTPConnect, with industry matched funding from major pharmaceutical companies and BABS at UNSW.
Members of the BABS faculty are Program participants and steering committee members of The Bridge Program.
Applications for the 2021 Program can be found https://research.qut.edu.au/bridge/
The Bridge and BridgeTech REDI Program
The MTPConnect Researcher Exchange and Development within Industry (REDI) Initiative, supported by the Medical Research Future Fund (MRFF), focusses on developing the skills and training of Australia’s medical technology, biotechnology, pharmaceutical and digital health sectors.
The Bridge and BridgeTech REDI Program provides for 20 funded industry placement fellowships per year for early- and mid-career researchers, academics and entrepreneurs.
Applications for the 2021 REDI Program can be found at https://research.qut.edu.au/bridge/
Industry Mentoring Network in STEM (IMNIS)
UNSW is a member of the IMNIS Program Mentoring which connects motivated second and third year PhD students and early career post-doctoral fellows (mentees) in science, technology, engineering and mathematics (STEM) with influential, high-level industry leaders (mentors) in a one-year industry mentoring and professional development program.
Current second and third year PhD students and early career post-doctoral fellows wanting to increase their understanding of industry, build their skills, professional networks and understanding of their future opportunities can visit https://research.unsw.edu.au/career-and-development and enquire at the Graduate Research School at email@example.com.
Australian Postgraduate Research Intern (APR.Intern) is Australia’s only national PhD internship program spanning all sectors and disciplines. Supported by the Australian Government, the program connects PhD students with industry through short-term paid research projects, empowering students to thrive in a practical research environment. For businesses, APR.Intern is a platform to access Australia’s brightest research talent and tap into new worlds of innovation.
UNSW is a founding shareholder of Cicada Innovations, Australia’s pioneer deep tech incubator which supports aspiring entrepreneurs and employees of startups and deep tech innovators to validate, commercialise and scale high impact technologies globally. Seminars, workshops, mentoring and networking events are available. Cicada also supports the Emerge tech & STEM Careers Expo for students. https://www.cicadainnovations.com/emerge2020
Our BABS courses benefit from the input of experts in the industry. Guest lecturers provide relevant experience, information and perspective, and offer opportunities to engage with industry. Some of BABS current guest lecturers include:
- Dr Philip Bell, Head of Research - Microbiogen, for BABS2011 Current Trends in Biotechnology
- Professor Alison Todd, Chief Scientific Office & Founder, SpeeDx Pty Ltd, for BABS2011 Current Trends in Biotechnology
- Phil Hayes-St Clair, Co-Founder & CEO, Drop Bio, for BABS3071 Commercial Biotechnology
- Sylvie Tso, Principal, Spruson & Ferguson Lawyers Pty Ltd, for BABS3071 Commercial Biotechnology
- Simon Uzcilas, Director, Four Hats Capital Pty Ltd, for BABS3071 Commercial Biotechnology
- James Brown, CFO, Bondi Bio, for BABS3071 Commercial Biotechnology
- John Martin, Chairman, BioPoint / Former CEO of Regeneus, for BABS3071 Commercial Biotechnology